Lv2
150 积分 2023-06-20 加入
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study
2小时前
待确认
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN
3小时前
已完结
983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
1个月前
已完结
983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
1个月前
已关闭
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
皖公网安备34019202002308
